[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.240.230. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Toubiana  J, Poirault  C, Corsia  A,  et al. Outbreak of Kawasaki disease in children during COVID-19 pandemic: a prospective observational study in Paris, France. medRxiv. Preprint posted May 2020. doi:10.1101/2020.05.10.20097394
2.
Riphagen  S, Gomez  X, Gonzalez-Martinez  C, Wilkinson  N, Theocharis  P.  Hyperinflammatory shock in children during COVID-19 pandemic.   Lancet. 2020;395(10237):1607-1608. doi:10.1016/S0140-6736(20)31094-1PubMedGoogle ScholarCrossref
3.
Belhadjer  Z, Méot  M, Bajolle  F,  et al.  Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic.   Circulation. 2020;382:1370-22. doi:10.1161/CIRCULATIONAHA.120.048360PubMedGoogle Scholar
4.
Verdoni  L, Mazza  A, Gervasoni  A,  et al.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.   Lancet. Published online May 13, 2020. doi:10.1016/S0140-6736(20)31103-XPubMedGoogle Scholar
5.
Viner  RM, Whittaker  E.  Kawasaki-like disease: emerging complication during the COVID-19 pandemic comment.   Lancet. Published online May 13, 2020. doi:10.1016/S0140-6736(20)31129-6Google Scholar
6.
European Centre for Disease Prevention and Control. Rapid risk assessment: paediatric inflammatory multisystem syndrome and SARS -CoV-2 infection in children. Published May 15, 2020. Accessed May 22, 2020. https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystem-syndrome-and-sars-cov-2-rapid-risk-assessment
7.
Royal College of Paediatrics and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. Accessed May 22, 2020. https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19
8.
World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19. Published May 15, 2020. Accessed May 22, 2020. https://www.who.int/publications-detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
9.
Centers for Disease Control and Prevention. Emergency preparedness and response: health alert network. Published May 14, 2020. Accessed May 22, 2020. https://emergency.cdc.gov/han/2020/han00432.asp
10.
McCrindle  BW, Rowley  AH, Newburger  JW,  et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention.  Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association.   Circulation. 2017;135(17):e927-e999. doi:10.1161/CIR.0000000000000484PubMedGoogle ScholarCrossref
11.
Katzelnick  LC, Gresh  L, Halloran  ME,  et al.  Antibody-dependent enhancement of severe dengue disease in humans.   Science. 2017;358(6365):929-932. doi:10.1126/science.aan6836PubMedGoogle ScholarCrossref
12.
Liu  L, Wei  Q, Lin  Q,  et al.  Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection.   JCI Insight. 2019;4(4):S6. doi:10.1172/jci.insight.123158PubMedGoogle ScholarCrossref
13.
Levin  M, Holland  PC, Nokes  TJ,  et al.  Platelet immune complex interaction in pathogenesis of Kawasaki disease and childhood polyarteritis.   Br Med J (Clin Res Ed). 1985;290(6480):1456-1460. doi:10.1136/bmj.290.6480.1456PubMedGoogle ScholarCrossref
14.
Menikou  S, Langford  PR, Levin  M.  Kawasaki disease: the role of immune complexes revisited.   Front Immunol. 2019;10:1156. doi:10.3389/fimmu.2019.01156PubMedGoogle ScholarCrossref
15.
Nagelkerke  SQ, Kuijpers  TW.  Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all?   Front Immunol. 2015;5(8232):674. doi:10.3389/fimmu.2014.00674PubMedGoogle Scholar
16.
Mayadas  TN, Tsokos  GC, Tsuboi  N.  Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury.   Circulation. 2009;120(20):2012-2024. doi:10.1161/CIRCULATIONAHA.108.771170PubMedGoogle ScholarCrossref
17.
Pathan  N, Franklin  JL, Eleftherohorinou  H,  et al.  Myocardial depressant effects of interleukin 6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase.   Crit Care Med. 2011;39(7):1692-1711. doi:10.1097/CCM.0b013e3182186d27PubMedGoogle ScholarCrossref
18.
Pathan  N, Hemingway  CA, Alizadeh  AA,  et al.  Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock.   Lancet. 2004;363(9404):203-209. doi:10.1016/S0140-6736(03)15326-3PubMedGoogle ScholarCrossref
19.
Nozawa  T, Imagawa  T, Ito  S.  Coronary-artery aneurysm in tocilizumab-treated children with Kawasaki’s disease.   N Engl J Med. 2017;377(19):1894-1896. doi:10.1056/NEJMc1709609PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Views 81,359
    Citations 0
    Original Investigation
    June 8, 2020

    Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

    Author Affiliations
    • 1Department of Paediatrics, Imperial College Healthcare NHS Trust, London, United Kingdom
    • 2Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London, London, United Kingdom
    • 3Department of Paediatric Infectious Diseases, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
    • 4Infection, Immunity, and Inflammation Department, UCL Great Ormond Street Institute of Child Health, London, United Kingdom
    • 5Department of Paediatric Infectious Diseases, Evelina London Children’s Hospital, London, United Kingdom
    • 6Department of Women and Children’s Health, School of Life Course Sciences, Kings College London, London, United Kingdom
    • 7Faculty of Medicine and Institute for Life Sciences, University of Southampton and NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
    • 8Children’s Acute Transport Service, Great Ormond Street Hospital for Children, London, United Kingdom
    • 9Paediatric Cardiology Services, Royal Brompton Hospital, London, United Kingdom
    • 10Department of Congenital Heart Disease, Evelina London Children’s Hospital, London, United Kingdom
    • 11Institute in Child Health, King’s College Hospital, London, United Kingdom
    • 12Paediatric Critical Care Unit, Nottingham Children’s Hospital, Nottingham, United Kingdom
    • 13Cardiology, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
    • 14Paediatric Intensive Care, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
    • 15Paediatric Intensive Care, Evelina London Children’s Hospital, London, United Kingdom
    • 16Kawasaki Disease Research Center, Department of Pediatrics, University of California San Diego
    JAMA. Published online June 8, 2020. doi:10.1001/jama.2020.10369
    Key Points

    Question  What are the clinical and laboratory characteristics of critically ill children who developed an inflammatory multisystem syndrome during the coronavirus disease 2019 pandemic?

    Findings  This case series included 58 hospitalized children, a subset of whom required intensive care, and met definitional criteria for pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (PIMS-TS), including fever, inflammation, and organ dysfunction. Of these children, all had fever and nonspecific symptoms, such as abdominal pain (31 [53%]), rash (30 [52%]), and conjunctival injection (26 [45%]); 29 (50%) developed shock and required inotropic support or fluid resuscitation; 13 (22%) met diagnostic criteria for Kawasaki disease; and 8 (14%) had coronary artery dilatation or aneurysms. Some clinical and laboratory characteristics had important differences compared with Kawasaki disease, Kawasaki disease shock syndrome, and toxic shock syndrome.

    Meaning  These findings help characterize the clinical features of hospitalized, seriously ill children with PIMS-TS and provide insights into this apparently novel syndrome.

    Abstract

    Importance  In communities with high rates of coronavirus disease 2019, reports have emerged of children with an unusual syndrome of fever and inflammation.

    Objectives  To describe the clinical and laboratory characteristics of hospitalized children who met criteria for the pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PIMS-TS) and compare these characteristics with other pediatric inflammatory disorders.

    Design, Setting, and Participants  Case series of 58 children from 8 hospitals in England admitted between March 23 and May 16, 2020, with persistent fever and laboratory evidence of inflammation meeting published definitions for PIMS-TS. The final date of follow-up was May 22, 2020. Clinical and laboratory characteristics were abstracted by medical record review, and were compared with clinical characteristics of patients with Kawasaki disease (KD) (n = 1132), KD shock syndrome (n = 45), and toxic shock syndrome (n = 37) who had been admitted to hospitals in Europe and the US from 2002 to 2019.

    Exposures  Signs and symptoms and laboratory and imaging findings of children who met definitional criteria for PIMS-TS from the UK, the US, and World Health Organization.

    Main Outcomes and Measures  Clinical, laboratory, and imaging characteristics of children meeting definitional criteria for PIMS-TS, and comparison with the characteristics of other pediatric inflammatory disorders.

    Results  Fifty-eight children (median age, 9 years [interquartile range {IQR}, 5.7-14]; 20 girls [34%]) were identified who met the criteria for PIMS-TS. Results from SARS-CoV-2 polymerase chain reaction tests were positive in 15 of 58 patients (26%) and SARS-CoV-2 IgG test results were positive in 40 of 46 (87%). In total, 45 of 58 patients (78%) had evidence of current or prior SARS-CoV-2 infection. All children presented with fever and nonspecific symptoms, including vomiting (26/58 [45%]), abdominal pain (31/58 [53%]), and diarrhea (30/58 [52%]). Rash was present in 30 of 58 (52%), and conjunctival injection in 26 of 58 (45%) cases. Laboratory evaluation was consistent with marked inflammation, for example, C-reactive protein (229 mg/L [IQR, 156-338], assessed in 58 of 58) and ferritin (610 μg/L [IQR, 359-1280], assessed in 53 of 58). Of the 58 children, 29 developed shock (with biochemical evidence of myocardial dysfunction) and required inotropic support and fluid resuscitation (including 23/29 [79%] who received mechanical ventilation); 13 met the American Heart Association definition of KD, and 23 had fever and inflammation without features of shock or KD. Eight patients (14%) developed coronary artery dilatation or aneurysm. Comparison of PIMS-TS with KD and with KD shock syndrome showed differences in clinical and laboratory features, including older age (median age, 9 years [IQR, 5.7-14] vs 2.7 years [IQR, 1.4-4.7] and 3.8 years [IQR, 0.2-18], respectively), and greater elevation of inflammatory markers such as C-reactive protein (median, 229 mg/L [IQR 156-338] vs 67 mg/L [IQR, 40-150 mg/L] and 193 mg/L [IQR, 83-237], respectively).

    Conclusions and Relevance  In this case series of hospitalized children who met criteria for PIMS-TS, there was a wide spectrum of presenting signs and symptoms and disease severity, ranging from fever and inflammation to myocardial injury, shock, and development of coronary artery aneurysms. The comparison with patients with KD and KD shock syndrome provides insights into this syndrome, and suggests this disorder differs from other pediatric inflammatory entities.

    ×